IL291891A - Prodrugs of myeloperoxidase inhibitors - Google Patents

Prodrugs of myeloperoxidase inhibitors

Info

Publication number
IL291891A
IL291891A IL291891A IL29189122A IL291891A IL 291891 A IL291891 A IL 291891A IL 291891 A IL291891 A IL 291891A IL 29189122 A IL29189122 A IL 29189122A IL 291891 A IL291891 A IL 291891A
Authority
IL
Israel
Prior art keywords
group
remaining
substituted
unsubstituted
nmr
Prior art date
Application number
IL291891A
Other languages
English (en)
Hebrew (he)
Inventor
Gene M Dubowchik
Joseph Theodore Lundquist Iv
Melody A Mcwherter
Jeffrey C Pelletier
Allen B Reitz
Eric Strobel
Yan Zhang
Original Assignee
Biohaven Therapeutics Ltd
Gene M Dubowchik
Joseph Theodore Lundquist Iv
Melody A Mcwherter
Jeffrey C Pelletier
Allen B Reitz
Eric Strobel
Yan Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd, Gene M Dubowchik, Joseph Theodore Lundquist Iv, Melody A Mcwherter, Jeffrey C Pelletier, Allen B Reitz, Eric Strobel, Yan Zhang filed Critical Biohaven Therapeutics Ltd
Publication of IL291891A publication Critical patent/IL291891A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
IL291891A 2019-10-10 2020-10-09 Prodrugs of myeloperoxidase inhibitors IL291891A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962913417P 2019-10-10 2019-10-10
PCT/US2020/054896 WO2021072140A1 (en) 2019-10-10 2020-10-09 Prodrugs of myeloperoxidase inhibitors

Publications (1)

Publication Number Publication Date
IL291891A true IL291891A (en) 2022-06-01

Family

ID=75438074

Family Applications (1)

Application Number Title Priority Date Filing Date
IL291891A IL291891A (en) 2019-10-10 2020-10-09 Prodrugs of myeloperoxidase inhibitors

Country Status (11)

Country Link
US (1) US20240067651A1 (cg-RX-API-DMAC7.html)
EP (1) EP4041735A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022552834A (cg-RX-API-DMAC7.html)
KR (1) KR20220080133A (cg-RX-API-DMAC7.html)
CN (1) CN114945573A (cg-RX-API-DMAC7.html)
AU (1) AU2020363903A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022006381A2 (cg-RX-API-DMAC7.html)
CA (1) CA3157260A1 (cg-RX-API-DMAC7.html)
IL (1) IL291891A (cg-RX-API-DMAC7.html)
MX (1) MX2022004203A (cg-RX-API-DMAC7.html)
WO (1) WO2021072140A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022010902A (es) * 2020-03-05 2022-10-07 Biohaven Therapeutics Ltd Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa.
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012797A1 (en) * 1989-04-19 1990-11-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Sulfer-containing xanthine derivatives as adenosin antagonists
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
WO2007069924A1 (en) * 2005-12-15 2007-06-21 Industrial Research Limited Deazapurine analogs of 4'-aza-l-nucleosides
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
NZ604423A (en) * 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオン誘導体
DK3265448T3 (da) * 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
SG11202000086PA (en) * 2017-07-17 2020-02-27 Astrazeneca Ab Mpo inhibitors for use in medicine

Also Published As

Publication number Publication date
JP2022552834A (ja) 2022-12-20
AU2020363903A1 (en) 2022-03-24
MX2022004203A (es) 2022-07-04
CA3157260A1 (en) 2021-04-15
EP4041735A4 (en) 2023-11-22
KR20220080133A (ko) 2022-06-14
CN114945573A (zh) 2022-08-26
WO2021072140A1 (en) 2021-04-15
US20240067651A1 (en) 2024-02-29
BR112022006381A2 (pt) 2022-06-28
EP4041735A1 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
EP2862581B1 (en) Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
MD4166539T2 (ro) Compuși care conțin nitril pentru utilizare în calitate de medicamente
JP6882996B2 (ja) オキシステロールおよびそれらの使用の方法
CA3104298A1 (en) Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
US11603377B2 (en) MTORC1 modulators and uses thereof
AU2021434797B2 (en) Amino acid derivative, preparation method therefor, and pharmaceutical composition for treating hepatitis, comprising same
AU2017229591B2 (en) Calpain modulators and methods of production and use thereof
AU2017326466B2 (en) Ketone inhibitors of lysine gingipain
US20240067651A1 (en) Prodrugs of myeloperoxidase inhibitors
CN112218878A (zh) Ntcp抑制剂
WO2019108673A1 (en) Compounds for treating near vision disorders
US20250034194A1 (en) Inhibitors of abnormal phosphorylation and tau protein aggregation
JP2025505975A (ja) ニコチネート及びニコチンアミドリボシドベースの化合物及びその誘導体
CA3134518A1 (en) Arginine gingipain inhibitors
RU2842241C1 (ru) Производное аминокислоты, способ его получения и содержащая его фармацевтическая композиция для лечения гепатита
RU2842241C9 (ru) Производное аминокислоты, способ его получения и содержащая его фармацевтическая композиция для лечения гепатита
EP4592276A1 (en) Novel acyloxymethyl prodrugs of psilocin and related 4-hydroxytryptamines obtained by an efficient synthetic approach
HK1240913B (en) Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
HK1209628B (en) Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid